Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pay-for-delay

- PMLiVE

Abbott offers up to $495m for Russia’s Veropharm

Acquisition will add to its generics portfolio

- PMLiVE

Teva restructures to stengthen unit identities

First major change at Israeli firm since Erez Vigodman’s appointment as CEO

- PMLiVE

Lundbeck agrees $658m deal to buy Chelsea Therapeutics

Acquisition boosts Danish firm's neurology profile and presence in US

European Commission launches mHealth consultation

May lead to policy action by 2015

- PMLiVE

Teva launches first generic of GSK’s Lovaza in US

Will have six months of marketing exclusivity for copy of cardiovascular drug

- PMLiVE

Sun Pharma offers $4bn for Ranbaxy

Follows period of manufacturing problems at Daiichi-owned Indian generics company

eHealth not up to speed in Europe

Less than one in three doctors email their patients and just 10 per cent hold online consultations

- PMLiVE

Abilify Maintena launches in Europe

Schizophrenia treatment is a key product to help Lundbeck replace lost Cipralex sales

EU flag

European Commission sets out HIV/Aids action plan

Says two-year programme proves HIV/Aids remains an EU health policy priority

- PMLiVE

Generic for Lilly’s Evista in US ‘within a month’

Teva to launch copy of osteoporosis drug

- PMLiVE

Five companies breach ABPI code

Lundbeck, A Menarini Pharma, Bayer, HRA Pharma UK and GlaxoSmithKline named by PMCPA

mHealth could be ‘the future’ of healthcare

EC says Europe is preparing for the mHealth revolution

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links